Molecular Diagnostics for Transplant Market Share

ID: MRFR/MED/10305-CR

128 Pages

Rahul Gotadki

June 2023

Molecular Diagnostics for Transplant Market Research Report Information by Product (Reagents & Kits, Instruments, and Services & Software), by Technology (Polymerase Chain Reaction (PCR), Sequencing, Microarray, and Others), by End User (Hospitals and Transplant Centers, Research Laboratories & Academic Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, And...

Molecular Diagnostics for Transplant Market Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Download PDF

Market Share

Molecular Diagnostics for Transplant Market Share Analysis

In 2020, global estimates from GLOBOCAN 2020, compiled by the International Agency for Research on Cancer (IARC), indicated approximately 19.3 million new cancer cases and around 10.0 million cancer-related deaths worldwide. The molecular diagnostics for transplant market is also significantly influenced by the increasing cases of COVID-19. According to the Organ Procurement & Transportation Network (OPTN), the US witnessed 41,354 organ transplants in 2021, marking a 5.9% increase from 2020 and the first time the annual total exceeded 40,000 in the country. This rise in transplant procedures is a key driver for market growth. Governments worldwide are increasingly focusing on promoting organ donation and transplantation. In 2022, the National Organ Transplant Programme (NOTP) of the Government of India initiated a program to encourage organ donation and transplantation across the country. The program encompasses financial support for establishing State Organ and Tissue Transplant Organizations (SOTTOs) in each State/UT, setting up National/Regional/State Bio-material centers, establishing new Organ Transplant/retrieval facilities, strengthening existing Organ Transplant/retrieval facilities, providing Transplant Coordinators to medical colleges and trauma centers, supporting the maintenance of deceased donors, ensuring dignified funerals for deceased donors, and offering post-transplant immune-suppressant drugs to Below Poverty Line (BPL) patients. Similarly, other governing bodies are adopting such programs to enhance public awareness about organ donations and transplantations. These initiatives and promotional campaigns are expected to present significant opportunities in the field. As medical advancements continue, there's a growing emphasis on enhancing organ transplantation technologies. Innovations in molecular diagnostics play a pivotal role in ensuring successful transplants. The precision and reliability offered by techniques like Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS) contribute to improved compatibility assessments and post-transplant monitoring. These technologies enable a closer examination of a patient's genetic makeup, aiding in Human Antigen Leucocyte (HLA) testing essential for transplantation. The rising integration of these advanced diagnostics enhances transplant outcomes and aligns with the increasing demand for organ transplants globally. Governments and healthcare organizations are recognizing the significance of fostering these advancements to address the rising challenges posed by chronic diseases and infectious agents.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

How much is the molecular diagnostics for transplant market?

The Molecular Diagnostics for Transplant Market is anticipated to reach 1.40 billion at a CAGR of 8.91% during the forecast period of 2024-2030.

How big is the US molecular diagnostics for transplant market?

The US is expected to hold a 35-40% share of the global market for molecular diagnostics for transplant market during the forecast period of 2024-2030.

What is the growth rate of the molecular diagnostics for transplant market?

The molecular diagnostics for transplant market is expected to grow at a 8.91% CAGR during the forecast period from 2024 to 2030.

Which region held the largest market share in the molecular diagnostics for transplant market?

The North America region market held the largest market share in molecular diagnostics for transplant market.

Who are the key players in the molecular diagnostics for transplant market?

The key players include Thermo Fisher Scientific Inc. (US), BioMérieux SA (France), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), Abbott Laboratories, Inc. (US), and others.

Which product segment led the molecular diagnostics for transplant market?

The reagents & kits product segment led the product segment in the molecular diagnostics for transplant market.

Which technology had the largest market share in the molecular diagnostics for transplant market?

Polymerase chain reaction (PCR) technology segment had the largest market share with over 40% market share.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

The Global Molecular Diagnostics for Transplant Market is projected to grow from 0.86 USD Billion in 2024 to 2.15 USD Billion by 2035, reflecting a robust growth trajectory.

Key Market Trends & Highlights

Molecular Diagnostics for Transplant Key Trends and Highlights

The market is expected to expand at a compound annual growth rate (CAGR) of 8.66% from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 2.15 USD Billion, indicating substantial growth potential.
In 2024, the market is valued at 0.86 USD Billion, laying a solid foundation for future expansion.
Growing adoption of molecular diagnostics due to the increasing need for precise transplant compatibility testing is a major market driver.

Molecular Diagnostics for Transplant Market

CAGR

8.66%

Market Size & Forecast

2024 Market Size	0.86 (USD Billion)
2035 Market Size	2.15 (USD Billion)
CAGR (2025-2035)	8.66%
Largest Regional Market Share in 2024	latin_america)

Major Players

Thermo Fisher Scientific Inc. (US), BioMérieux SA (France), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), Hoffmann-La Roche Ltd. (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), Abbott Laboratories, Inc. (US)

Market Trends

Increasing prevalence of infectious diseases market growth

There has been an increasing prevalence of infectious diseases owing to various factors such as climate change, rapid urbanization, microbial evolution, among others. Special care needs to be taken before transplantation as a transplant patient can get any type of infection caused by bacteria, viruses, fungi and parasites. These include influenza virus infection, urinary tract infection, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr virus, Human herpesvirus 6, among several others. Moreover, increasing antimicrobial resistance is also a cause of serious concern and has been adding to the increasing prevalence of infectious disease.

For instance, according to the Centers for Disease Control and Prevention, more than 2.8 million antimicrobial-resistant infections occur in the US each year. Thus, increasing prevalence of infectious disease has driven the demand for implementation of thorough molecular diagnostics in transplantation, thereby, driving the market.

Moreover, the number of patients suffering from various types of cancers such as lung, blood, breast, and liver is increasing worldwide. In 2020, according to GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC), an estimated number of 19.3 million new cancer cases and about 10 million cancer deaths occurred globally.

Hence, the growing number of cancer patients and rising incidences of infectious diseases are increasing the demand for organ transplantation.

The increasing emphasis on personalized medicine and the need for precise donor-recipient matching are driving advancements in molecular diagnostics for transplant procedures.

U.S. Food and Drug Administration (FDA)

Molecular Diagnostics for Transplant Market Market Drivers

Market Growth Projections

The Global Molecular Diagnostics for Transplant Market Industry is projected to experience substantial growth over the next decade. With a market value of 0.86 USD Billion in 2024, it is anticipated to expand to 2.15 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 8.66% from 2025 to 2035, driven by various factors including technological advancements, increasing transplant procedures, and heightened awareness of personalized medicine. The market's expansion reflects the critical role of molecular diagnostics in enhancing transplant outcomes and patient care.

Rising Incidence of Infectious Diseases

The growing incidence of infectious diseases poses a challenge for transplant recipients, thereby driving the Global Molecular Diagnostics for Transplant Market Industry. Transplant patients are particularly vulnerable to infections due to immunosuppressive therapies, necessitating the need for rapid and accurate diagnostic tools to detect infections early. The demand for molecular diagnostics that can identify pathogens quickly and effectively is increasing, as timely intervention is crucial for patient survival. This trend is expected to contribute to market growth, as healthcare providers seek reliable diagnostic solutions to manage the health of transplant patients.

Growing Awareness of Personalized Medicine

The increasing emphasis on personalized medicine is shaping the Global Molecular Diagnostics for Transplant Market Industry. Healthcare providers and patients are becoming more aware of the benefits of tailored treatment plans based on genetic and molecular profiles. This shift towards individualized care enhances the effectiveness of transplant procedures and minimizes the risk of complications. As a result, the demand for molecular diagnostics that can provide insights into patient-specific responses to treatment is on the rise. This trend is expected to contribute significantly to the market's growth, as healthcare systems increasingly adopt personalized approaches to transplant management.

Regulatory Support and Funding for Research

Government initiatives and funding for research in the field of molecular diagnostics are pivotal for the Global Molecular Diagnostics for Transplant Market Industry. Regulatory bodies are increasingly recognizing the importance of molecular diagnostics in improving transplant outcomes, leading to streamlined approval processes for new diagnostic tools. Additionally, public and private funding for research and development in this area is on the rise, fostering innovation and accelerating the introduction of advanced diagnostic solutions. This supportive environment is likely to enhance market growth, as new technologies and methodologies are developed to address the complexities of transplant medicine.

Increasing Prevalence of Transplant Procedures

The rising incidence of organ transplant procedures globally is a primary driver for the Global Molecular Diagnostics for Transplant Market Industry. As more patients require organ transplants due to conditions such as end-stage renal disease and liver failure, the demand for effective diagnostic tools increases. In 2024, the market is valued at approximately 0.86 USD Billion, reflecting the urgent need for precise molecular diagnostics to ensure successful transplant outcomes. This trend is expected to continue, with projections indicating that the market could reach 2.15 USD Billion by 2035, highlighting the critical role of molecular diagnostics in managing transplant patients.

Technological Advancements in Diagnostic Tools

Innovations in molecular diagnostic technologies significantly enhance the capabilities of the Global Molecular Diagnostics for Transplant Market Industry. Advances such as next-generation sequencing and real-time PCR allow for more accurate and rapid detection of organ rejection and infection. These technologies facilitate personalized medicine approaches, improving patient outcomes and reducing healthcare costs. The integration of artificial intelligence in diagnostic processes further streamlines workflows and enhances accuracy. As these technologies evolve, they are likely to drive market growth, contributing to a projected compound annual growth rate of 8.66% from 2025 to 2035.

Market Segment Insights

Molecular Diagnostics for Transplant Product Insights

The Molecular Diagnostics for Transplant Market segmentation, based on product, includes reagents & kits, instruments, and services & software. The reagents & kits segment held the largest market in 2021, with a market share of 42.77%, and is expected to register the highest CAGR from 2022 to 2030. Molecular diagnostic reagents include disease-specific kits and standard reagents that are used during infectious disease diagnosis and pathogen screening. Laboratory technicians utilize specific disease diagnostic kits for earlier and more precise identification of specific pathogen strains in a patient sample.

Standard reagents are key components of the majority of conventional molecular diagnostic procedures. Therefore, companies are now launching rapid reagents & kits to detect the novel coronavirus to fuel the growth of this market.

March 2022 Immucor, Inc. (US) launched innovative transplant diagnostics MIA FORA NGS EXPRESS HLA Typing Software in order to provide a faster and easier NGS analysis experience.

Molecular Diagnostics for Transplant Technology Insights

The Molecular Diagnostics for Transplant Market data has been segmented, based on technology, by polymerase chain reaction (PCR), sequencing, microarray, and others. The polymerase chain reaction (PCR) segment held the largest market in 2021, with a market share of ~35%, reaching a market value of around 0.5 billion by 2030. The sequencing segment is expected to register the highest CAGR of 10.59% from 2022 to 2030. Polymerase Chain Reaction (PCR) technology is used to identify a disease by analyzing the genetic and proteomic parameters such as deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) in humans or the case of infections.

Additionally, it plays a crucial role in disease diagnostics and is considered to be one of the most developed molecular techniques which have a wide range of applications in the medicine field and for broad-spectrum pathogen detection and evaluation of emerging novel infections and surveillance.

October 2022: Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

Figure 2: Molecular Diagnostics for Transplant Market, by Technology, 2023 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Molecular Diagnostics for Transplant End User Insights

Based on end user, the global molecular diagnostics for transplant industry has been segmented into the hospitals and transplant centers, research laboratories & academic institutes, and others. The hospitals and transplant centers segment held the largest market in 2021 and is expected to register the highest CAGR of 9.73% from 2022 to 2030. Hospitals and transplant centers witness significant growth due to the rising demand for novel tissue transplantation for treating organ failure, increasing demand for transplant products like tissue products, immunosuppressants, organ preservation solutions, and technological advancements.

Healthcare-associated infections (HAIs) occur in all settings of care, such as ambulatory clinics, hospitals as well as nursing homes, and rehabilitation facilities.

Get more detailed insights about Molecular Diagnostics for Transplant Market Research Report—Global Forecast till 2030

Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America molecular diagnostics for transplant market accounted for the largest market share in 2021, due to rising demand technology evolution and increasing incidences of chronic diseases that lead to an increase in organ transplants. According to research, the number of kidneys, liver, heart, lung, pancreas, and intestine transplants is increasing in the US, while the number of kidney transplants is increasing in Canada.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%) BY REGION 2023

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe molecular diagnostics for transplant market accounts for the second-largest market share owing to the rising prevalence of chronic diseases, including kidney, cardiovascular diseases (CVD), and respiratory diseases. Advancements in molecular diagnostics have improved the identification and understanding of specific gene defects for the appropriate organ transplant in kidney, heart, and lung failure. CVD diseases are influenced by factors such as atherosclerosis, blood clots, diabetes, a sedentary lifestyle, and obesity, which may lead to cardiac failure. In 2019, the European Society of Cardiology (ESC) Atlas estimated that Europe reports 11 million new cases suffering from CVD each year.

Furthermore, the Germany molecular diagnostics for transplant market held the largest market share, and the UK molecular diagnostics for transplant market was the second largest to hold the market share in the Europe region.

The Asia-Pacific molecular diagnostics for transplant market is expected to grow at a significant share from 2022 to 2030. The region's growing geriatric population demands organ transplantation, which may vary as per organ failure. In 2020, according to the World Economic Forum, China, India, and Japan had the oldest populations globally. Furthermore, it has been estimated that by 2050, one in four aged people will be living in the region. Moreover, China molecular diagnostics for transplant market held the largest market share, and the India molecular diagnostics for transplant market was the fastest growing market in the Asia-Pacific region.

Key Players and Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the molecular diagnostics for transplant market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the molecular diagnostics for transplant industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Thermo Fisher Scientific Inc. (US) specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, and specialty diagnostics. The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the laboratory's productivity. In September 2021, the company announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

Key Companies in the Molecular Diagnostics for Transplant Market market include

Industry Developments

October 2022 Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

February 2022 Bio-Techne Corporation (US) entered into an agreement with Thermo Fisher Scientific, Inc. (US) in order to develop and commercialize the ExoTRU Kidney Transplant Rejection Test.

In September 2021 Thermo Fisher Scientific Inc. (US) announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

Future Outlook

Molecular Diagnostics for Transplant Market Future Outlook

The Global Molecular Diagnostics for Transplant Market is projected to grow at 8.66% CAGR from 2024 to 2035, driven by technological advancements, increasing transplant procedures, and rising demand for personalized medicine.

New opportunities lie in:

Develop next-generation sequencing platforms for enhanced donor-recipient matching.
Implement AI-driven analytics for predictive transplant outcomes.
Expand point-of-care testing solutions to improve accessibility and speed of diagnostics.

By 2035, the market is poised for robust growth, reflecting advancements in molecular diagnostics and increased transplantation rates.

Market Segmentation

Molecular Diagnostics for Transplant Product Outlook

Reagents & Kits
Instruments
Services & Software

Molecular Diagnostics for Transplant End User Outlook

Hospitals and Transplant Centers
Research Laboratories & Academic Institutes
Others

Molecular Diagnostics for Transplant Regional Outlook

North America

US
Canada

Molecular Diagnostics for Transplant Technology Outlook

Polymerase Chain Reaction (PCR)
Sequencing
Microarray
Others

Report Scope

Report Attribute/Metric	Details
Market Size 2021	USD 0.66 billion
Market Size 2022	USD 0.71 billion
Market Size 2030	USD 1.40 billion
Compound Annual Growth Rate (CAGR)	8.91% (2024-2030)
Base Year	2023
Forecast Period	2024-2030
Historical Data	2018 & 2020
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product, Technology, End User, and Region
Geographies Covered	North America, Europe, Asia Pacific, and Rest of the World
Countries Covered	The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Thermo Fisher Scientific Inc. (US), BioMérieux SA (France), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), Abbott Laboratories, Inc. (US), and others
Key Market Opportunities	Growing public awareness about organ donation and transplantation
Key Market Drivers	Increasing prevalence of infectious diseasesAdvancements in molecular diagnostic techniquesIncreasing number of transplant procedures

Market Highlights

Author

Rahul Gotadki

Assistant Manager

She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Latest Comments

John Doe

john@example.com

This is a great article! Really helped me understand the topic better.

Posted on July 23, 2025, 10:15 AM

Jane Smith

jane@domain.com

Thanks for sharing this. I’ve bookmarked it for later reference.

Posted on July 22, 2025, 7:45 PM

View All